NanoXplore Announces Appointment of New Board Member

NanoXplore Inc. (" NanoXplore " or the " Corporation ") (TSX-V: GRA and OTCQX: NNXPF) is pleased to announce the appointment of Jodie Morgan to its Board of Directors.

Ms. Morgan has an impressive background as a strategic President and CEO and Board member of several companies, including currently as a Director of Bartek Ingredients Inc., the world's largest producer of malic acid and food-grade fumaric acid—specialty products that improve flavour profiles, food safety and profitability in foods and beverages, among other things. She is also currently the CEO and a Director of GreenMantra, an upcycling technology leader in the circular economy of plastics. Ms. Morgan is a member of the National Association of Corporate Directors and Women Corporate Directors in the United States and has degrees in engineering and in business with a concentration in finance.

Rob Wildeboer, Chairman of NanoXplore, commented:

" We are absolutely thrilled to have Jodie join the NanoXplore family. Her significant experience in growing companies will undoubtedly help the Corporation achieve long-term success . "

NanoXplore also announces that it has granted a total of 100,000 stock options of the Corporation to Ms. Morgan, exercisable at a price of $3.75 per share, for a period of five years. The options will vest in three installments, one third upon issuance, one third after one year following issuance, and the last third two years following issuance. The options are granted pursuant to and in accordance with the Corporation's stock option plan.

About NanoXplore Inc.

NanoXplore is a graphene company, a manufacturer and supplier of high-volume graphene powder for use in industrial markets. The company provides standard and custom graphene-enhanced plastic and composite products to various customers in transportation, packaging, electronics, and other industrial sectors. NanoXplore is headquartered in Montreal, Quebec with manufacturing facilities across Canada, the United States and Europe.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information, please contact:

Soroush Nazarpour
President & CEO
NanoXplore Inc.
+1 (514) 935-1677
info@NanoXplore.ca


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

The Conversation (0)
Longeveron Granted Small or Medium-sized Enterprise  Status by the European Medicines Agency

Longeveron Granted Small or Medium-sized Enterprise Status by the European Medicines Agency

Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company has been granted Small or Medium-sized Enterprise (SME) status by the European Medicines... Keep Reading...
Longeveron® Announces Contract Development and Manufacturing Business and First Contract

Longeveron® Announces Contract Development and Manufacturing Business and First Contract

Contract manufacturing services as a new business line has the potential to generate approximately $4-5 million in annual revenues First manufacturing services contract signed with Secretome Therapeutics Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company... Keep Reading...
Immatics Announces First Quarter 2024 Financial Results and Business Update

Immatics Announces First Quarter 2024 Financial Results and Business Update

Company Provides Clinical Data Update from Ongoing Phase 1 Clinical Trial with ACTengine® IMA203 TCR-T Targeting PRAME Updated clinical data on ACTengine® IMA203 targeting PRAME in 30 heavily pre-treated metastatic melanoma patients at RP2D: 55% confirmed objective response rate, including tumor... Keep Reading...
Sona's 'THT' Cancer Therapy to be Assessed for Efficacy and Ability to Act as a Catalyst to Generate Immune Responses in Research Study

Sona's 'THT' Cancer Therapy to be Assessed for Efficacy and Ability to Act as a Catalyst to Generate Immune Responses in Research Study

Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce an innovative research initiative to be undertaken with The Giacomantonio Immuno-Oncology Research Group (the "Research Group"). This study aims to evaluate the efficacy of Sona's Targeted... Keep Reading...
Why Invest in Nanotech Stocks?

Why Invest in Nanotech Stocks?

The nanotechnology market is experiencing a promising stage of growth, making it an attractive space for investors.From nanotech-based solar panels that increase energy efficiency to pharmaceutical products that make use of nanotech in drug-delivery systems, nanotechnology has far-reaching... Keep Reading...

SILO Pharma Inc

SILO Pharma Inc is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research. Keep Reading...

Interactive Chart

Latest Press Releases

Related News